FRED Fore Research, Evidence & Development Beta Version with Sample Data

Mission: keep the plixorafenib competitive landscape continuously current, visible, and trustworthy — a living, cited, repeatable resource, never scattered or rebuilt ad hoc. Every week, a what-changed delta-scan runs across the tracked competitors (readouts, label changes, confirmatory data, safety, approvals, earnings, new entrants), refreshing each dossier’s data-cut and flagging material changes for sign-off; a full rebuild follows SNO / ASCO / EHA readouts, label changes, and earnings. Competitor data is public + cited; plixorafenib’s own figures stay Fore-internal and are never fabricated.

Updated 20 Jul 2026. The tovorafenib dossier goes from 8 to 14 sections, answering the slide-review items: development trajectory beyond FIREFLY, label age scope, the ORR-primary endpoint, guideline positioning, commercial field infrastructure, and KOL perception. Two corrections worth knowing: the label has no upper age limit in either the FDA or EMA indication — “up to 25” is FIREFLY-1 trial eligibility, not label text — and CONNECT TarGeT-B is not a Day One study (NCT07206849, sponsored by Nationwide Children’s, readout not before May 2030). New alongside it: an age-specific incidence and outcome report for four CNS histologies, whose headline is that only pilocytic astrocytoma can honestly be charted. Plixorafenib comparison cells remain Fore-internal placeholders pending cleared data.